CD4+ T-Cell Lymphoma Harboring a Chimeric Antigen Receptor Integration in TP53.

IF 96.2 1区医学 Q1 MEDICINE, GENERAL & INTERNAL

New England Journal of Medicine Pub Date : 2025-02-06 DOI:10.1056/NEJMoa2411507

Karlo Perica, Nayan Jain, Michael Scordo, Ruchi Patel, Ozgur Can Eren, Utsav Patel, Gunes Gundem, Dylan Domenico, Sneha Mitra, Nicholas D Socci, John K Everett, Aoife M Roche, Angelina Petrichenko, Gunjan L Shah, Maria E Arcila, Laetitia Borsu, Jae H Park, Steven M Horwitz, Sergio A Giralt, Ahmet Dogan, Christina Leslie, Elli Papaemmanuil, Frederic D Bushman, Saad Z Usmani, Michel Sadelain, Sham Mailankody

引用次数: 0

Abstract

Malignant T-cell transformation after chimeric antigen receptor (CAR) T-cell therapy has been described, but the contribution of CAR integration to oncogenesis is not clear. Here we report a case of a T-cell lymphoma harboring a lentiviral integration in a known tumor suppressor, TP53, which developed in a patient with multiple myeloma after B-cell maturation antigen (BCMA) CAR T-cell therapy.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

New England Journal of Medicine 医学-医学：内科

CiteScore

145.40

自引率

0.60%

发文量

1839

审稿时长

1 months

期刊介绍： The New England Journal of Medicine (NEJM) stands as the foremost medical journal and website worldwide. With an impressive history spanning over two centuries, NEJM boasts a consistent publication of superb, peer-reviewed research and engaging clinical content. Our primary objective revolves around delivering high-caliber information and findings at the juncture of biomedical science and clinical practice. We strive to present this knowledge in formats that are not only comprehensible but also hold practical value, effectively influencing healthcare practices and ultimately enhancing patient outcomes.